J. Blake Bartlett - Concepedia

Author

J. Blake Bartlett

Also Known As

J B Bartlett, J Bartlett, J Blake Bartlett, J. B. Bartlett, J. Bartlett, J. Blake Bartlett, J.B. Bartlett, Justin Blake Bartlett

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

St George's Hospital St George's, University of London Bristol-Myers Squibb (Switzerland)OhioHealth The University of Texas Southwestern Medical Center

About

J. Blake Bartlett is an author at St George's Hospital specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	1.9K
2	Immunology	12	12	1.5K
3	Pathology	6	6	446
4	Cell Biology	4	4	581
5	Health Sciences	3	3	104

J. Blake Bartlett

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells Lei Wu, Mary Adams, Troy Carter, Clinical Cancer Research	2008	431
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells Christine Galustian, B Meyer, Marie‐Christine Labarthe, Cancer Immunology Immunotherapy Anti-cancer AgentsCancer ImmunosurveillanceMedicineT-regulatory CellImmunology	2008	384
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma Stephen Schey, Paul Fields, J. Blake Bartlett, Journal of Clinical Oncology	2004	309
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Keith Dredge, Rebecca Horsfall, Simon P. Robinson, Microvascular Research InflammationAngiogenesisMedicineEndothelial Cell MigrationAkt Phosphorylation	2005	268
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions Ling Lu, Faribourz Payvandi, Lei Wu, Microvascular Research OncologyAngiogenesisAnti-cancer Drug LenalidomideMedicineEndothelial Cell Function	2008	221
Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response Antonia Lopez‐Girona, Daniel Heintel, Ling‐Hua Zhang, British Journal of Haematology Potential Mechanistic LinkMixed-phenotype Acute LeukemiaImmunologyImmune RegulationCell Death	2011	177
Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function Anita K. Gandhi, Jingfen Kang, Lori Capone, Current Cancer Drug Targets ImmunologyImmune RegulationImmunotherapeuticsImmune SystemImmunotherapy	2010	167
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo Liang Zhang, Zhengzi Qian, Zhen Cai, American Journal of Hematology ApoptosisImmunologyNk CellsCell DeathImmunotherapy	2009	147
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers J. Blake Bartlett, A Michael, Ian Clarke, British Journal of Cancer ImmunologyPathologyRevimid Trade MarkMetronomic ChemotherapyImmunotherapy	2004	139
The Synthetic Compound CC-5079 Is a Potent Inhibitor of Tubulin Polymerization and Tumor Necrosis Factor-α Production with Antitumor Activity Linghua Zhang, Lei Wu, Heather K. Raymon, Cancer Research Antitumor ActivityChemoprevention StrategyImmunologyCell DeathCancer Biology	2006	90

Page 1